<br /> CHEMOCENTRYX 24 HOUR DEADLINE ALERT: FORMER LOUISIANA ATTORNEY GENERAL AND KAHN SWICK & FOTI, LLC REMIND INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Deadline in Class Action Lawsuits Against ChemoCentryx, Inc. – CCXI<br />

CHEMOCENTRYX 24 HOUR DEADLINE ALERT: FORMER LOUISIANA ATTORNEY GENERAL AND KAHN SWICK & FOTI, LLC REMIND INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Deadline in Class Action Lawsuits Against ChemoCentryx, Inc. – CCXI

PR Newswire

NEW ORLEANS

,

July 5, 2021

/PRNewswire/ — Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of

Louisiana

,

Charles C. Foti, Jr.

, remind investors that they have only until

July 6, 2021

to file lead plaintiff applications in securities class action lawsuits against ChemoCentryx, Inc. (NasdaqGS: CCXI), if they purchased the Company’s shares between

November 26, 2019

and

May 6, 2021

, inclusive (the “Class Period”). These actions are pending in

the United States

District Court for the Northern District of

California

.

What You May Do

If you purchased shares of ChemoCentryx and would like to discuss your legal rights and how these cases might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (

[email protected]

), or visit

https://www.ksfcounsel.com/cases/nasdaqgs-ccxi/

to learn more. If you wish to serve as a lead plaintiff in the class actions, you must petition the Courts by

July 6, 2021

.

About the Lawsuits

ChemoCentryx and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws. On

May 4, 2021

, the U.S. Food and Drug Administration issued briefing documents regarding the Company’s drug candidate, avacopan, noting that “[c]omplexities of the study design…raise questions about the interpretability of the data to define a clinically meaningful benefit of avacopan” and that the review had “identified several areas of concern, raising uncertainty about the interpretability of the data and the clinical meaningfulness of these results.” On this news, shares of ChemoCentryx plummeted approximately 45%, to close at

$26.63

per share on

May 4, 2021

.

The first-filed case is

Homyk v. ChemoCentryx, Inc., et al

., No. 3:21-cv-03343.

About Kahn Swick & Foti, LLC

KSF, whose partners include former

Louisiana

Attorney General

Charles C. Foti, Jr.

, is one of the nation’s premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking to recover investment losses due to corporate fraud and malfeasance by publicly traded companies. KSF has offices in

New York

,

California

and

Louisiana

.